TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
3.880
-0.080 (-2.02%)
At close: Aug 10, 2026, 4:00 PM EDT
3.990
+0.110 (2.84%)
After-hours: Aug 10, 2026, 7:34 PM EDT
TransCode Therapeutics Employees
TransCode Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 5 or 71.43% compared to the previous year.
Employees
12
Change (1Y)
5
Growth (1Y)
71.43%
Revenue / Employee
n/a
Profits / Employee
-$3,641,348
Market Cap
3.69M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | 5 | 71.43% | 12 | 0 |
| Dec 31, 2024 | 7 | -3 | -30.00% | 7 | 0 |
| Sep 30, 2024 | 8 | -2 | -20.00% | 8 | 0 |
| Dec 31, 2023 | 10 | -9 | -47.37% | 10 | 0 |
| Dec 31, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Dec 31, 2021 | 9 | 3 | 50.00% | 8 | 1 |
| Sep 30, 2021 | 7 | 1 | 16.67% | 7 | 0 |
| Jun 30, 2021 | 6 | 0 | - | 2 | 4 |
| Mar 31, 2021 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| PMGC Holdings | 34 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Galmed Pharmaceuticals | 6 |
| Jupiter Neurosciences | 5 |
| Creative Medical Technology Holdings | 4 |
| Mustang Bio | 4 |
RNAZ News
- 21 days ago - TransCode Therapeutics Transcript: AGM 2026 - Transcripts
- 24 days ago - TransCode Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - TransCode Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - TransCode Therapeutics Slides: Investor presentation - Filings
- 7 weeks ago - TransCode Therapeutics Slides: Investor presentation - Filings
- 2 months ago - TransCode Therapeutics to Host R&D Webcast on June 18, 2026 - PRNewsWire
- 2 months ago - Transcode reports results from Phase 1a dose escalation trial with TTX-MC138 - TheFly
- 2 months ago - TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PRNewsWire